Immunome Inc reports results for the quarter ended March 31 - Earnings Summary

Immunome

12/05/2025 21:53

Immunome Inc IMNM.OQ reported a quarterly adjusted loss of 52 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.51.  The mean expectation of nine analysts for the quarter was for a loss of 68 cents per share. Wall Street expected results to range from -89 cents to -49 cents per share.

Revenue rose 184.4% to $2.93 million from a year ago; analysts expected $285.71 thousand.

Immunome Inc's reported EPS for the quarter was a loss of 52 cents​.

The company reported a quarterly loss of $41.64 million.

Immunome Inc shares had risen by 10.8% this quarter and lost 29.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.2% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunome Inc is $23.00

This summary was machine generated from LSEG data May 12 at 08:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.68
-0.52
Beat
Dec. 31 2024
-0.58
-1.28
Missed
Sep. 30 2024
-0.56
-0.78
Missed
Jun. 30 2024
-0.39
-0.60
Missed